Evidence map›Paper›PMID 34518549›Full record

ArticleNature communications2021

OPTN is a host intrinsic restriction factor against neuroinvasive HSV-1 infection.

Joshua Ames, Tejabhiram Yadavalli, Rahul Suryawanshi, James Hopkins, Alexander Agelidis, Chandrashekhar Patil, Brian Fredericks, Henry Tseng, Tibor Valyi-Nagy, Deepak Shukla

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 62 citations in OpenAlex.

  1. Cell death network regulation in HSV infection: immune evasion versus host defense.Apoptosis : an international journal on programmed cell death · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Akt isoform specificity drives intrinsic immune regulation during HSV-1 infection.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Joshua AmesDepartment of Microbiology and Immunology, University of Illinois at Chicago, College of Medicine, Chicago, IL, USA.
Tejabhiram YadavalliDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago, College of Medicine, Chicago, IL, USA.ORCID 0000-0001-8584-2685
Rahul SuryawanshiDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago, College of Medicine, Chicago, IL, USA.
James HopkinsDepartment of Microbiology and Immunology, University of Illinois at Chicago, College of Medicine, Chicago, IL, USA.
Alexander AgelidisDepartment of Microbiology and Immunology, University of Illinois at Chicago, College of Medicine, Chicago, IL, USA.ORCID 0000-0002-6582-1630
Chandrashekhar PatilDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago, College of Medicine, Chicago, IL, USA.ORCID 0000-0002-5641-4523
Brian FredericksDepartment of Pathology, University of Illinois at Chicago, College of Medicine, Chicago, IL, USA.
Henry TsengDuke Eye Center and Department of Ophthalmology, Duke University Medical Center, Durham, NC, USA.ORCID 0000-0001-6951-1229
Tibor Valyi-NagyDepartment of Pathology, University of Illinois at Chicago, College of Medicine, Chicago, IL, USA.
Deepak ShuklaDepartment of Microbiology and Immunology, University of Illinois at Chicago, College of Medicine, Chicago, IL, USA. dshukla@uic.edu.ORCID 0000-0002-3039-6953
University of Illinois Chicago · USDuke Medical Center · USIllinois College · US

Funding

Translational Core for Therapeutic and Diagnostic DevelopmentP30EY001792 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI AAKALU, VINAY · 1985 to 2025
$14.8M
A new molecular therapy against ocular herpesR01EY024710 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI DEEPAK SHUKLA · 2015 to 2026
$5.2M
HPSE in Ocular Herpes InfectionR01EY029426 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI DEEPAK SHUKLA · 2018 to 2026
$3.7M
A small molecule inhibitor of HSV genital infectionsR01AI139768 · NIAID · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SHUKLA, DEEPAK · 2018 to 2021
$1.6M
Negative regulation of NF-kB by optineurin in primary open angle glaucomaK08EY021520 · NEI · DUKE UNIVERSITY · PI TSENG, HENRY · 2011 to 2013
$526k
NEI NIH HHS K08 EY021520NEI NIH HHS P30 EY001792NEI NIH HHS R01 EY024710NEI NIH HHS R01 EY029426NIAID NIH HHS R01 AI139768
6 · The paper itself

Abstract

Fast-replicating neurotropic herpesviruses exemplified by herpes simplex virus-1 (HSV-1) naturally infect the central nervous system (CNS). However, most individuals intrinsically suppress the virus during a primary infection and preclude it from significantly damaging the CNS. Optineurin (OPTN) is a conserved autophagy receptor with little understanding of its role in neurotropic viral infections. We show that OPTN selectively targets HSV-1 tegument protein, VP16, and the fusion glycoprotein, gB, to degradation by autophagy. OPTN-deficient mice challenged with HSV-1 show significant cognitive decline and susceptibility to lethal CNS infection. OPTN deficiency unveils severe consequences for recruitment of adaptive immunity and suppression of neuronal necroptosis. Ocular HSV-1 infection is lethal without OPTN and is rescued using a necroptosis inhibitor. These results place OPTN at the crux of neuronal survival from potentially lethal CNS viral infections.

Indexed as

AnimalsAutophagyCell Cycle ProteinsCells, CulturedCentral Nervous SystemChlorocebus aethiopsHeLa CellsHerpes SimplexHerpesvirus 1, HumanHumansMembrane Transport ProteinsMiceMice, Inbred C57BLMice, KnockoutNecroptosisNeuronsCell Cycle ProteinsMembrane Transport ProteinsNeuroprotective AgentsOptn protein, mouse

Identifiers

PMID34518549
PMCPMC8437952
OpenAlexW3200674328

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.